J&J case: Government asks ‘victims’ to approach central or state panel

NEW DELHI: The government Tuesday issued a public notice stating that patients suffering from disability due to faulty articular surface replacement (ASR) hip implants can approach either the central expert committee or the state-level panel.

In case the affected patients intend to approach the central expert committee, they may write to the legal cell of the Central Drugs Standard Control Organisation, FDA Bhavan on Kotla Road, New Delhi.

They may send an email on legalcell@cdsco.nic.in.

If the affected patients approach the state-level committee, they may write to the concerned state drug controller who will be the member secretary of the state-level committee.

The Centre, earlier this month, constituted the central expert committee under the chairmanship of R K Arya, director of Sports Injury Centre at Safdarjung Hospital, to determine the quantum of compensation to be given to patients who have faulty hip implants, manufactured by DePuy International, a subsidiary of Johnson & Johnson.

Apart from the five-member expert panel, the Union Health Ministry has asked principle/health secretaries of all the states and the Union Territories to constitute separate committees so that they can receive such complaints from the affected patients.

The move came after a panel, constituted earlier by the Union Health Ministry to investigate complaints about articular surface replacement (ASR) hip implant devices, said in its report that the pharma giant “suppressed” facts on the harm of surgeries afterwards, which was conducted on patients in India using “faulty” hip replacement systems.

It had also suggested that the company pay compensation of around Rs 20 lakh to the affected patients. Some of the patients who had suffered due to the faulty implants had questioned the panel’s recommendation of the paltry amount, saying it was like “rubbing salt into their wounds”.

The Health Ministry, in its order dated August 30, has asked the central expert committee to submit its recommendation to the Central Drugs Standard Control Organisation (CDSCO) within 45 days of receiving recommendations from the state-level panels.

The order had said a committee under the chairmanship of Arun Kumar Aggarwal has given its report which has been accepted by the central government with certain modifications.

“Now the central government has decided to constitute a central expert committee to determine the quantum of compensation, as admissible under the law, in respect of faulty ASR hip implants manufactured by M/s DePuy International Limited, UK and implanted in India,” the had order said.

  • Related Posts

    To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

    New ‘Bible’ of Nearly ‘Ideal’ Eating hit stands to become Instant Best Seller New Delhi: You are a veritable Hamlet when it comes to the question, to eat or not…

    Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

    Bharat Mandapam witnessed Spectacle of Crazy Innovations by Maker of Ssi Mantra, Best in class Surgical Robot New Delhi: It was a veritable display of innovative potential and prowess of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert